Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to 608.89%.

  • Agios Pharmaceuticals' EBITDA Margin rose 5564100.0% to 608.89% in Q4 2025 from the same period last year, while for Dec 2025 it was 873.87%, marking a year-over-year increase of 2926000.0%. This contributed to the annual value of 873.87% for FY2025, which is 2926000.0% up from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' EBITDA Margin is 608.89%, which was up 5564100.0% from 907.37% recorded in Q3 2025.
  • Agios Pharmaceuticals' EBITDA Margin's 5-year high stood at 608.89% during Q4 2025, with a 5-year trough of 12156.85% in Q1 2022.
  • Over the past 4 years, Agios Pharmaceuticals' median EBITDA Margin value was 1295.97% (recorded in 2023), while the average stood at 2068.27%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 105413600bps in 2023, then crashed by -976300bps in 2025.
  • Quarter analysis of 4 years shows Agios Pharmaceuticals' EBITDA Margin stood at 2300.97% in 2022, then soared by 35bps to 1496.23% in 2023, then rose by 22bps to 1165.3% in 2024, then surged by 48bps to 608.89% in 2025.
  • Its EBITDA Margin was 608.89% in Q4 2025, compared to 907.37% in Q3 2025 and 1020.12% in Q2 2025.